Cargando…
Targeting MDM2–p53 Axis through Drug Repurposing for Cancer Therapy: A Multidisciplinary Approach
[Image: see text] Cancer remains a major cause of morbidity and mortality worldwide, and while current therapies, such as chemotherapy, immunotherapy, and cell therapy, have been effective in many patients, the development of novel therapeutic options remains an urgent priority. Mouse double minute...
Autores principales: | Ghafoor, Naeem Abdul, Yildiz, Aysegul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536845/ https://www.ncbi.nlm.nih.gov/pubmed/37779953 http://dx.doi.org/10.1021/acsomega.3c03471 |
Ejemplares similares
-
Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017) -
Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis
por: Lai, Chunwei W., et al.
Publicado: (2022) -
Mouse modelling of the MDM2/MDMX−p53 signalling axis
por: Tackmann, Nicole R., et al.
Publicado: (2017) -
The MDM2/MDMX/p53 axis in the adaptive stress response
por: Wang, Bing, et al.
Publicado: (2020) -
HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status
por: Ou, Wen-Bin, et al.
Publicado: (2015)